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Abstract
Background: Macrophages play diverse roles in mammary gland development and breast cancer. CC-chemokine
ligand 2 (CCL2) is an inflammatory cytokine that recruits macrophages to sites of injury. Although CCL2 has been
detected in human and mouse mammary epithelium, its role in regulating mammary gland development and
cancer risk has not been explored.
Methods: Transgenic mice were generated wherein CCL2 is driven by the mammary epithelial cell-specific mouse
mammary tumour virus 206 (MMTV) promoter. Estrous cycles were tracked in adult transgenic and non-transgenic
FVB mice, and mammary glands collected at the four different stages of the cycle. Dissected mammary glands were
assessed for cyclical morphological changes, proliferation and apoptosis of epithelium, macrophage abundance and
collagen deposition, and mRNA encoding matrix remodelling enzymes. Another cohort of control and transgenic
mice received carcinogen 7,12-Dimethylbenz(a)anthracene (DMBA) and tumour development was monitored
weekly. CCL2 protein was also quantified in paired samples of human breast tissue with high and low
mammographic density.
Results: Overexpression of CCL2 in the mammary epithelium resulted in an increased number of macrophages,
increased density of stroma and collagen and elevated mRNA encoding matrix remodelling enzymes lysyl oxidase
(LOX) and tissue inhibitor of matrix metalloproteinases (TIMP)3 compared to non-transgenic controls. Transgenic
mice also exhibited increased susceptibility to development of DMBA-induced mammary tumours. In a paired
sample cohort of human breast tissue, abundance of epithelial-cell-associated CCL2 was higher in breast tissue of
high mammographic density compared to tissue of low mammographic density.
Conclusions: Constitutive expression of CCL2 by the mouse mammary epithelium induces a state of low level
chronic inflammation that increases stromal density and elevates cancer risk. We propose that CCL2-driven
inflammation contributes to the increased risk of breast cancer observed in women with high mammographic
density.
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Background
Development and function of the mammary gland is
dependent upon dynamic interactions between the
mammary gland epithelium and surrounding stroma.
Macrophages are a major component of the stroma, and
have the capacity to direct a diverse range of biological
processes necessary for mammary gland development,
including cell proliferation, differentiation, phagocytosis,
and tissue remodelling [1–6]. In addition to roles in
healthy development, macrophages may also affect can-
cer susceptibility [7, 8]. Macrophages suppress cancer
development as part of innate and adaptive anti-tumour
immune responses, through recognition of DNA dam-
aged cells, phagocytosis and antigen presentation to
tumour-specific T cells [9–11]. On the other hand,
macrophages can promote the proliferation and survival
of cancer cells, facilitate tumour cell invasion, increase
angiogenesis, and upregulate the production of pro-
tumourigenic factors, and thus promote tumour
progression [12–14]. In order to exert this wide range of
effects in healthy development and cancer susceptibility
in the mammary gland, macrophages respond to a
variety of different signals in their local microenvironment,
including cytokines emanating from other cell types, and
components of the extracellular matrix.
CC-chemokine ligand 2 (CCL2), also known as mono-
cyte chemotactic protein 1, is a small pro-inflammatory
cytokine and is a highly potent chemoattractant for
monocytes and macrophages to sites of tissue injury and
inflammation [15, 16]. CCL2 can be highly expressed by
both the tumour and surrounding stromal cells in breast
carcinomas [17–19]. CCL2 expression in breast carcin-
omas is highly associated with macrophage infiltration,
and its expression is correlated with poor prognosis in
breast cancer patients [18–21]. Studies in mice have
implicated CCL2 of epithelial tumour cell origin, and
macrophages expressing the CCL2 receptor, CCR2, as
critical factors in metastasis of breast cancer to the bone
and lungs [19, 22]. These studies suggest that epithelial
cell-derived CCL2 in carcinomas might promote tumour
invasion and metastasis through increased infiltration of
macrophages into tumours.
Less understood is the role of CCL2 in healthy breast
development and how this may relate to the risk of
cancer initiation. CCL2 protein is detected in human
breast epithelium [17, 18] and may be responsible for
macrophage recruitment under specific conditions. To
investigate the effect of CCL2 in mammary gland devel-
opment and function, we developed a transgenic mouse
model Mmtv-Ccl2, whereby CCL2 is constitutively
expressed by the mammary epithelium. We found that
these mice exhibit increased macrophage recruitment to
the mammary gland, perturbed mammary morphogen-
esis at the proestrus phase of the ovarian cycle and
increased abundance of stroma. Overexpression of CCL2
also increased susceptibility to 7,12-Dimethylbenz(a)an-
thracene (DMBA)-induced mammary tumour develop-
ment. These key features of the mouse model resemble
breast tissue with high mammographic density in
women, which is associated with increased stroma and
collagen deposition [23, 24], increased immune cell
abundance [25], and a fourfold to six-fold increased risk
of breast cancer when adjusted for body mass index
(BMI) and age [26]. A paired sample analysis of human
breast tissue of high and low mammographic density
showed that CCL2 protein is higher in tissue with high
mammographic density. Combined, these findings sug-
gest that high mammographic density and the associated
increased cancer risk may be the result of CCL2-driven
inflammation.
Methods
Mice
Animal experiments were approved by the University of
Adelaide Animal Ethics Committee and were conducted
in accordance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (7th ed.,
2004). All mice were maintained in specific pathogen-free
conditions with controlled light (12-h light, 12-h dark
cycle) and temperature at the Laboratory Animal Services
Medical School facility. Food and water were provided ad
libitum. In the experiments we utilised Mmtv-Ccl2 trans-
genic mice on an FVB background and non-transgenic
FVB mice as controls. Estrous cycle stage was determined
by analysis of vaginal smears as described previously [27].
Estrous cycles were tracked for at least 28 days.
Generation of Mmtv-Ccl2 transgenic mice
The Mmtv-Ccl2 transgenic mouse, in which the mouse
mammary tumour virus 206 promoter (Mmtv) long
terminal repeat (generously provided by Dr. William
Muller, McGill University) constitutively drives the
expression of the chemokine (C-C motif ) ligand 2 (Ccl2)
mRNA, was generated at the Albert Einstein College of
Medicine (New York, USA) by Jiufeng Li. The Mmtv-
Ccl2 expression cassette was constructed by insertion of
a 3.2-kb EcoRI fragment of the mouse genomic Ccl2
cDNA from the construct pMMJE + 20 [28] into the
EcoRI site of the plasmid MMTV-SV40-Bssk, which
contain regulatory elements of the Mmtv promoter
followed by the SV40 poly A site and the ampicillin-
resistance gene (ampr) [29]. DH5-α cells were
transformed with this construct by heat shock and
selected for ampicillin resistance. DNA was extracted
from the successfully transformed cells and the
Mmtv-Ccl2 expression cassette was released as a PVUII
fragment of 8 kb in size. This purified Mmtv-Ccl2
expression cassette was micro-injected into zygotes of
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FVB mice, which were then transferred into pseudo-
pregnant recipient mothers.
Twenty-nine offspring were generated, and three
founder lines (Mmtv-Ccl2 #13, #20 and #29) were identi-
fied by PCR screening using a primer pair (forward: 5’-
CGT CCA GAA AAC CAC AGT CA -3’; reverse: 5’-
CCG CTC GTC ACT TAT CCT TC-3’) covering the
Mmtv promoter sequence, which produced a product
size of 196 bp (Fig. 1a). All three founders were cross-
bred with background strain FVB mice and the geno-
types of all progeny were confirmed by PCR. One female
pup was selected from each founder line and the
expression of Ccl2 mRNA from different tissues was
measured by RT-PCR using a primer pair that spanned
both endogenous genomic and exogenous cloned Ccl2
(forward: 5-CCC AAT GAG TAG GCT GGA GA-3’;
reverse: 5’-TCT GGA CCC ATT CCT TCT TG-3’) and
produced product sizes of 451 bp and 125 bp, respect-
ively (Fig. 1a). The offspring from founder 29 exhibited
highest expression of mRNA encoding Ccl2 in the
mammary gland and was chosen for further analysis. A
homozygous Mmtv-Ccl2 transgenic mouse line was
successfully established from founder 29 and maintained
for over five generations on a FVB background.
DMBA-induced tumour susceptibility
Susceptibility of mice to mammary gland tumours was
investigated using the DMBA-induced mammary tumour
model. This model is superior for this purpose over other
mouse mammary tumour models, such as transgenic
expression of polyoma middle T oncogene targeted to the
mammary mouse mammary gland, because tumour
development does not occur with 100% penetrance,
enabling quantification and statistical analysis of cancer
susceptibility. Mmtv-Ccl2 and FVB mice received DMBA
in sesame oil (1 mg/ml) weekly by oral gavage for 6 weeks
from 6 weeks of age. General health and signs of tumour
development were monitored weekly. To detect tumours,
the mammary glands were gently palpated. Mice were
killed when tumours were detected and the tumours
dissected, formalin-fixed and paraffin-embedded.
Tissue morphology and histology
To analyse the morphology of the mammary gland,
mammary glands were dissected from mice and spread
on a glass slide. The mammary gland whole mounts
were incubated in Carnoy’s fixative and stained in
carmine alum as described previously [30]. To analyse
mammary gland histology, mammary glands were
dissected from mice and fixed in 4% paraformaldehyde
(PFA) (Sigma-Aldrich) for 24 h at 4 °C. Paraffin-
embedded tissue was cut on a Leica Rotary Microtome
(Leica Microsystems) and placed onto SuperFrost Plus
slides. Slides were dried overnight at 37 °C. Blocks and
sections were stored at room temperature prior to
staining.
Haemotoxylin and eosin staining was performed on
paraffin-embedded sections. The sections were dewaxed
Fig. 1 Generation of mouse mammary tumour virus 206 transgenic mice (Mmtv-Ccl2). The Mmtv-Ccl2 expression cassette was detected in three of twenty-
nine mice by PCR screening and the expression of both endogenous genomic and cloned Ccl2 mRNA in different tissues was measured by RT-PCR with
product sizes of 451 bp and 125 bp, respectively (a). CCL2 protein detected by immunohistochemistry in the mammary gland from female offspring from
founder mouse #29 (b) compared to non-transgenic control (c). RNA encoding MMTV (d) and CCL2 (e), and CCL2 protein (f) were quantified in spleen (Sp),
kidney (Kid), ovary (Ov), liver (Liv), salivary gland (SG) and mammary gland (MG) from Mmtv-Ccl2 and non-transgenic control mice. Abundance of mRNA was
normalised to Actb expression, and is given in arbitrary units where the average of the non-transgenic mammary gland control is 1; n= 5 per group. Data are
presented as mean + SEM with statistical analysis conducted using the unpaired t test, *p< 0.05
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in Safsolv (Ajax, Finechem, Australia) and passed se-
quentially through 100%, 95%, 80% and 70% ethanol for
rehydration. The sections were stained with haemotoxy-
lin and counterstained with eosin and then mounted on
coverslips.
Masson’s Trichrome stain was used for detection of
collagen fibres in paraffin-embedded mouse mammary
gland tissue (all reagents were from Sigma-Aldrich).
Slides were placed in Bouin’s fluid overnight at room
temperature. The following day, slides were placed in
Weigert’s Haematoxylin working solution (50% A and
50% B) for 10 minutes at room temperature and
immersed in 80% ethanol before washing with MQ
water. Slides were placed in Biebrich Scarlet solution for
2 minutes and immersed in 5% phosphotungstic acid for
15 minutes followed by immersing in Light green
solution for 10 minutes. Slides were immersed in 1%
glacial acetic acid for 5 minutes prior to dehydration,
clearing and mounting.
Immunohistochemistry
Proliferating cells were identified by bromodeoxyuridine
(BrdU) immunostaining of paraffin-embedded mammary
gland tissue. One hour prior to sacrifice, mice received
an intraperitoneal (i.p.) injection of 100 μl of 10 mg/ml
BrdU (Sigma). Sections were stained for BrdU incorpor-
ation into DNA using a BrdU In-Situ Detection Kit
(BD Biosciences Pharmingen) according to the manufac-
turer’s instructions.
Apoptotic cells were identified by terminal deoxynu-
cleotidyl transferase dUTP nick end labelling (TUNEL)
staining of paraffin-embedded mammary gland tissue.
Sections were stained with the In-Situ Cell Death
Detection Kit (Roche) according to the manufacturer’s
instructions. Only BrdU and TUNEL positive cells
clearly located within the ductal or alveolar epithelium
were included in the analysis.
Macrophage abundance was determined by F4/80
antibody staining. Five micrometer paraffin-embedded
sections mounted on glass slides were incubated with rat
anti-F4/80 monoclonal antibody (1:100 dilution; overnight
at 4 °C) (Caltag Laboratories, Burlingame, CA, USA)
followed by biotinylated rabbit anti-rat IgG (1:200 dilution;
40 minutes at room temperature) (Vector Laboratories)
and ABC Elite kit (Vector Laboratories) with 3,3 diamino-
benzadine (DAB) peroxidase (DAKO, Denmark).
CCL2 was detected with polyclonal rabbit anti-mouse
CCL2 (Santa Cruz Biotechnology, CA, USA) in 5-μm
paraffin-embedded sections mounted on glass slides. For
antigen retrieval, slides were placed in 10 mM sodium
citrate buffer (pH 6) and brought to 90 °C in a water
bath for 20 minutes and washed two times in PBS for
3 minutes each. Following CCL2 antibody incubation
(1:50 dilution; overnight at 4 °C), sections were
incubated with goat anti-rabbit HRP (1:200 dilution;
Dako) for 60 minutes at room temperature. The
detection of bound antibody was performed using DAB
according to the manufacturer’s instructions.
Collagen-1 was detected using Alexa Fluor® 594 goat-
anti rabbit IgG (Chemicon, MA, USA, 1:800 dilution).
Slides stained with secondary antibodies only or with
isotype-matched antibody were included as negative
controls. All sections were mounted in fluorescent
mounting medium (Dako, Glostrup, Denmark) with 4’,6-
diamidino-2-phenylindol (DAPI) (Sigma, St Louis, USA)
and were stored at 4 °C in the dark until image capture.
Histology, pathology and immunohistochemistry
quantification
Fluorescence images of collagen-1 and TUNEL-positive
apoptotic epithelial cells were captured and collected
using FV10i Confocal Microscope (Olympus, USA) with
laser-power and photomultiplier settings kept constant
for all experiments, and images were captured at × 60
magnification. Non-fluorescent stained tissue sections
were captured as a digital image using a Nanozoomer
1.0 (Hamamatsu, Shizouka, Japan) at a zoom equivalent
to a × 40 objective lens. Whole mount images of
mammary glands were captured by MZ16 FA-Stereo
microscope (Leica, The University of Adelaide, SA, Australia).
An assessor blinded to mouse genotype performed all
quantification analysis. To determine the extent of
ductal branching morphogenesis in whole-mounted
mammary glands, the three longest ducts from each
mammary gland were selected, the number of branch
points on each duct was counted manually, and a mean
value of three ducts per mammary gland were calculated
and expressed as branch points/mm.
To quantify the extent of alveolar development in
H&E-stained sections, epithelium was categorized as
ductal (single epithelium layer) or alveolar (clusters of
epithelial structures containing alveolar lumens) and the
numbers of ductal and alveolar epithelial structures were
counted manually as described previously [31, 32]. The
total number of alveolar buds was expressed as percent-
age of total epithelial structures (ductal plus alveolar).
To determine the ratio of stroma and epithelium area
within the mammary gland in H&E-stained sections, five
ductal epithelium and alveolar epithelium regions were
randomly chosen for quantification. The area of stroma
and epithelium was measured and represented as stroma
area (mm2)/epithelium area (mm2). To determine the
number of epithelial cells within the ductal epithelium,
the number of haematoxylin-positive nuclei was counted.
To determine the deposition of collagen around
mammary epithelium, the amount of fibre stain (green)
around five randomly chosen ductal epithelia and alveo-
lar epithelia was quantified. To determine the number of
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proliferating epithelial cells and apoptotic epithelial cells,
the number of BrdU-positive cells and TUNEL-positive
cells within the epithelium was counted respectively.
The number of F4/80-positive cells in the mammary
gland was counted and only positive cells with visible
haematoxylin-stained nuclei were included. For F4/80
staining, F4/80-positive macrophages were distinguished
from F4/80-stained eosinophils on the basis of nuclear
morphology. All results were expressed as positive cells/
mm2 or percentage of positive cells. The mean density
of positive cells within the five ductal and the five
alveolar stroma regions was calculated, and grouped by
mouse genotype.
The thickness of total collagen (indicated by red
arrows) around each selected ductal epithelium was
measured, quantified and represented as collagen
thickness/μm (E). The intensity of collagen I was also
measured around each selected ductal epithelium, and
was quantified and represented as collagen I density
(arbitrary unit) (F). The mean fluorescence intensity
(mean grey-scale value) of collagen I was determined
and analysed using ImageJ software and a mean value of
five randomly chosen epithelial ducts was calculated.
Haemotoxylin and eosin stained sections of DMBA-
induced mammary tumours were assessed by a veterinary
pathologist (LW). The tumours were classified and scored
for mitotic index and inflammation grade. Mitotic index
was determined by counting the number of mitotic cells
in a 10× field of view. Inflammation was scored on a scale
of 0–5, which took into account degree of inflammation
and degree of dispersion as either 0 (none), 1 (mild, focal),
2 (mild, multifocal), 3 (moderate, focal), 4 (moderate,
multifocal) or 5 (marked, diffuse or multifocal).
CCL2 ELISA
All tissues and serum were collected under sterile
conditions, and the tissue was snap frozen in liquid
nitrogen and stored at −80 °C until processing. Protein
was extracted from tissues in RIPA buffer containing
Complete Protease Inhibitor Cocktail Tablets (Roche,
Basel, Switzerland). Protein concentration of each
sample was quantified using the BCA protein assay (Thermo
Scientific) following the manufacturer’s instructions. The
limit of detection was between 20 μg/ml and 2000 μg/ml.
A CCL2-specific sandwich ELISA (eBioscience, San
Diego, CA, USA) was used to quantify mouse CCL2
protein in different tissues, according to the manufac-
turer’s instructions. Briefly, an anti-mouse CCL2 anti-
body was coated onto a 96-well microtitre plate to
capture CCL2 from either recombinant standard or
assay samples. A biotinylated anti-mouse CCL2 detec-
tion antibody was then used and bound antibody was
quantified by the addition of streptavidin-conjugated
horseradish peroxidase (HRP), followed by the addition
of a chromagen substrate. After incubation for 20 mi-
nutes at room temperature, the substrate product was
acidified by the addition of 50 μl of 1 M HCl, and
absorbance at 450 nm (reference wavelength 570 nm)
was measured using a Benckmark™ microplate reader
(Bio-Rad Laboratories). The concentration of CCL2
within tissues and serum was then calculated from a
standard curve (five-parameter logistic curve) using
known concentrations of recombinant CCL2. This assay
was reported by the manufacturer to have a minimum de-
tection limit of 15 pg/ml, with intra-assay and inter-assay
precision of approximately 5%. The concentration of
CCL2 in each sample is expressed relative to the protein
concentration of the tissue, e.g. CCL2 (pg)/protein (pg).
mRNA expression
Spleen, mammary gland, kidney, ovary and salivary gland
were dissected from Mmtv-Ccl2 and FVB mice to quantify
expression of Ccl2, Mmtv, Mmp2, Mmp9, Lox, Timp1,
Timp2 and Timp3 mRNA expression. Total RNA was
extracted using Trizol (Invitrogen) and treated with DNase
(DNA free; Ambion), then first-strand cDNA was reverse
transcribed from 3 μg random hexamer-primed RNA
employing a Superscript-III Reverse Transcriptase kit.
Primer pairs specific for published cDNA sequences were
designed using Primer Express version 2 Software (Applied
Biosystems, Foster City, CA, USA). The following primer
pairs were used to detect specific cDNAs: Actb 5' GTG
TGA CGT TGA CAT CCG TAA AG 3' CTC AGG AGG
AGC AAT GAT CTT GAT; Ccl2 5' CCA GCA AGA TGA
TCC CAA TGA 3' TCT CTT GAG CTT GGT GAC AAA
AAC; Mmtv 5' CGT CCA GAA AAC CAC AGT CA 3'
CCG CTC GTC ACT TAT CCT TC; Mmp2 5' CAA GTT
CCC CGG CGA TGT C 3' TTC TGG TCA AGG TCA
CCT GTC;Mmp9 5' CAG ACG TGG GTC GAT TCC A 3'
TGT CTC GCG GCA AGT CTT C; Timp1 5' AGT CCC
AGA ACC GCA GTG AA 3' AGT ACG CCA GGG AAC
CAA GA; Timp2 5' GAG CCT GAA CCA CAG GTA CCA
3' GTC CAT CCA GAG GCA CTC ATC; Timp3 5’ CTT
CTG CAA CTC CGA CAT CGT 3’ TCA GAG GCT TCC
GTG TGA ATG; Lox 5’ TGC CAG TGG ATT GAT ATT
ACA GAT GT 3’ AGC GAA TGT CAC AGC GTA CAA.
PCR amplification was performed in duplicate in an ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems) using SYBR Green PCR Master Mix (Applied Biosys-
tems). Reaction products were analysed by dissociation
curve profile and by 2% agarose gel (wt/vol) electrophoresis.
Assay optimization and validation experiments were per-
formed to define the amplification efficiency of each primer
pair as described previously [33]. Messenger RNA abun-
dance values were normalized independently to ActbmRNA
expression, and data are plotted as relative expression in
arbitrary units, adjusted such that the mean of the wild-type
control group is assigned a value of 1.
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Quantification of CCL2 in paired human breast tissue
samples
To investigate the relationship between mammographic
density and CCL2, immunohistochemistry to detect
CCL2 was conducted on paired breast tissue samples of
high mammographic density (HMD) and low mammo-
graphic density (LMD). This approach has been de-
scribed previously [23, 25], and offers excellent scope to
study histological parameters associated with HMD in
small sample sizes, as paired-sample statistical analysis
can be applied.
Briefly, ethics approval from the Peter MacCallum
Human Research Ethics Committee (number 08/21) and
St. Vincent’s Hospital, Victoria was obtained and the
study conducted in accordance with the Australian
National Statement on Ethical Conduct in Human Re-
search. Breast tissue was collected from women under-
going prophylactic mastectomy for breast cancer
prevention consented to the study through the Victorian
Cancer Biobank (VCB 10010). These women had a con-
firmed BRCA1/2 carrier status, a past history of breast
cancer in the other breast or a family history of two or
more first-degree or second-degree relatives with breast
cancer who were diagnosed before the age of 50 years.
Resected breast tissue was transferred immediately on
ice to the pathology department upon completion of
mastectomy, where pathologists resected slices of breast
tissue using a sterile technique. X-rays of those slices
were taken by a breast radiographer using uniform
radiological parameters and were assessed against a cali-
bration ruler for selection of HMD and LMD regions.
The tissue slice was transferred to a biosafety level-2
hood, where areas that appeared white on X-rays were
selected and removed using sterile blades and defined as
HMD regions, and areas that appeared black were simi-
larly selected, removed and classified as LMD regions.
The HMD and LMD regions were subjected to routine
formalin fixation and paraffin embedding.
Paraffin-embedded human breast tissue sections were
placed on a hotplate at 60 °C for 60 minutes before
dewaxing in two 5-minute washes in Safsolv and
gradually passed through 100%, 95%, 80% and 70%
ethanol for rehydration as described previously [23, 25].
Before sections were incubated with mouse anti-human
CCL2 antibody (R&D systems) for 30 minutes at room
temperature, sections were placed in Dako EnVision™
low pH antigen retrieval solution (Dako) and brought to
90 °C in a water bath for 20 minutes followed by
Envision™ wash buffer and endogenous peroxidase block.
After primary antibody incubation, sections were
incubated with Dako EnVision™ HRP (ready-to-use,
Dako) for 30 minutes at room temperature and washed
in Envision™ wash buffer for 5 minutes. The detection of
bound antibody was performed according to the
manufacturer’s instructions. Tissue sections were coun-
terstained with haematoxylin prior to dehydration, and
cleared and mounted as described above. Slides stained
with isotype-matched primary antibody were included as
negative controls.
Stained tissue sections were captured as a digital
image using a Nanozoomer 1.0 (Hamamatsu, Shizouka,
Japan) at a zoom equivalent to a × 40 objective lens. All
quantification analysis was performed blinded. Three
epithelium clusters were randomly selected from each
section for quantification. To determine the intensity of
CCL2-positive staining within the epithelium of each
cluster, staining was quantified using the IHC profiler
within Image J analysis software. The percentage of
positive staining was determined by combining percent-
age of high, medium and low positive staining within
each selected epithelium measured by the IHC profiler
and the mean value of three clusters per patient was
calculated.
Statistical analysis
Data were assessed for normal distribution with a
Shapiro-Wilk normality test using GraphPad Prism 5
(GraphPad software Inc, San Diego, CA, USA) or SPSS
Statistics Version 17.0 (IBM Corporation, Armonk, NY,
USA). Normally distributed data were analysed using the
unpaired t test with the exception of paired high and
low mammographic density samples, which were ana-
lysed by paired t test. Not normally distributed data were
analysed using the Mann–Whitney U test. Data are pre-
sented as the mean ± SEM (standard error of mean).
Kaplan-Meier survival curves were generated using SPSS
Statistics Version 17.0 to analyse survival function and
the log rank test was used to compare different Kaplan–
Meier curves between groups. Tumour incidence was
analysed by the chi-squared test. The difference between
control and transgenic groups was considered statisti-
cally significant if p < 0.05 and is indicated on the figures
by an asterisk.
Results
Elevated expression of Ccl2 mRNA and protein in Mmtv-Ccl2
mice
To determine whether CCL2 abundance was elevated in
transgenic mice, mRNA encoding the MMTV promoter
and CCL2, and CCL2 protein, were investigated in
offspring from mouse founder line #29. CCL2 protein
was clearly detectable in the lumen of the mammary
gland of Mmtv-Ccl2 mice by immunohistochemistry,
and was substantially elevated compared to the very low
abundance in non-transgenic control mice (Fig. 1b and c).
No positive staining was observed in the mammary epi-
thelium stained with isotype-matched negative control
antibody (not shown). Messenger RNA encoding MMTV
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was virtually undetectable in the spleens, kidneys, ovaries
and livers of all mice, and in the mammary gland and sal-
ivary gland of non-transgenic control mice (Fig. 1d). How-
ever, abundance of mRNA encoding MMTV was
detectable in the mammary gland and salivary gland of
Mmtv-Ccl2 mice and was 15-fold and 125-fold higher, re-
spectively, compared to control mice.
Consistent with previous studies using CCL2 expression
cassettes driven by different promoters [34, 35], elevated
abundance of CCL2 was observed not only in the tissue of
interest, but also in other tissues and in the blood of
Mmtv-Ccl2 mice. Abundance of Ccl2 mRNA was
significantly elevated in the spleen, kidney, salivary gland,
mammary gland and liver of Mmtv-Ccl2 mice compared
to control mice (Fig. 1e). The abundance of CCL2 protein
was also elevated in the spleen, liver, salivary gland, and
mammary gland and in the serum of Mmtv-Ccl2 mice
compared to control mice (Fig. 1f).
CCL2 overexpression increases recruitment of
macrophages to the mammary gland
F4/80 immunohistochemistry was performed to investi-
gate the effect of epithelial cell-derived CCL2 on the
number of macrophages in the mammary gland. F4/80-
positive macrophages were observed in close proximity
to ductal and alveolar epithelium in the mammary
glands from both control (Fig. 2a and c, respectively)
and Mmtv-Ccl2 mice (Fig. 2b and d, respectively). No
positive staining was observed in the mammary glands
stained with isotype-matched irrelevant antibody (not
shown). The density of macrophages in regions sur-
rounding both ductal and alveolar epithelium was in-
creased in Mmtv-Ccl2 mice compared with control
(Fig. 2e).
CCL2 overexpression perturbs mammary gland
morphogenesis during the estrous cycle
CCL2 overexpression did not affect estrous cyclicity.
Estrous cycle length was (mean ± SEM) 5.4 ± 0.1 days for
both Mmtv-Ccl2 and control mice (n = 29 per genotype).
There was no significant difference between the two
groups in the percentage of time spent in each of the
four stages of the estrous cycle. To assess the impact of
CCL2 overexpression on mammary gland development
across the estrous cycle, adult mammary glands from
control and Mmtv-Ccl2 transgenic mice were dissected
at the different stages of the cycle and compared mor-
phologically and histologically (Fig. 3). Despite normal
secondary branching and alveolar architecture during
the development phase of the cycle (metestrus and dies-
trus) in transgenic mice, Mmtv-Ccl2 mice exhibited in-
creased density of branch points (Fig. 3k) and an
increase in the tissue area comprised by alveolar epithe-
lium (Fig. 3l) at the proestrus phase of the cycle, suggest-
ing a perturbation in the cyclic regression of the
mammary gland. Thus, mammary gland function at the
proestrus phase of the cycle was investigated in further
experiments.
To investigate the effect of CCL2 on epithelial cell
turnover at the proestrus phase of the cycle, mammary
glands from Mmtv-Ccl2 and control mice were stained
for BrdU, indicative of cell proliferation, and TUNEL,
indicative of cell death. BrdU-positive cells were ob-
served in both ductal and alveolar epithelium of
mammary glands from control (Fig. 4a and c, respect-
ively) and Mmtv-Ccl2 (Fig. 4b and d, respectively) mice.
There was no significant difference in the density of pro-
liferating ductal or alveolar epithelial cells in Mmtv-Ccl2
compared to control mice (Fig. 4i). TUNEL-positive cells
were observed in both ductal and alveolar epithelium of
Fig. 2 The effect of CCL2 overexpression on macrophage abundance and location within and around mammary epithelium. Paraffin sections of
mammary gland tissue from control and Mmtv-Ccl2 were stained with anti-macrophage-specific F4/80 antibody to detect macrophages in the
stroma surrounding ductal (a, b) and alveolar epithelium (c, d) of mammary glands from adult control and Mmtv-Ccl2 mice. Macrophages are
indicated by black arrows. The number of F4/80-positive macrophages was quantified and represented as F4/80-positive macrophages/mm2 (e);
n = 6 per group. Data are presented as mean + SEM with statistical analysis conducted using the unpaired t test, *p < 0.05
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mammary glands from control (Fig. 4e and g, respect-
ively) and Mmtv-Ccl2 (Fig. 4f and h, respectively) mice.
There was no significant difference in the density of
TUNEL-positive ductal or alveolar epithelial cells in
Mmtv-Ccl2 compared to control mice (Fig. 4j).
Upon further examination of H&E-stained thin
sections, an increased thickness of stroma surrounding
epithelial ducts was evident in the mammary glands of
transgenic mice. To investigate this, the ratio of stroma
to epithelium was quantified in H&E-stained sections
from control and Mmtv-Ccl2 mice at proestrus (Fig. 5a
and b, respectively). There was a twofold increase in the
area of stroma relative to epithelium in Mmtv-Ccl2
mice (Fig. 5c). The increase in stroma in CCL2-
overexpressing mice was further investigated by
analysing the extracellular matrix. The thickness of
collagen, assessed by Masson’s trichrome stain, in con-
trol and Mmtv-Ccl2 (Fig. 5d and e, respectively) mice
was increased (Fig. 5f ) however the abundance of
monomeric collagen 1 detected by collagen I antibody
staining was comparable in Mmtv-Ccl2 mice (Fig. 5g-i).
Quantitative RT-PCR was used to analyse the expression
of mRNA encoding enzymes that are involved in collagen
remodelling. The abundance of both lysyl oxidase (Lox)
and tissue inhibitor of metalloproteinase 3 (Timp3)
mRNA were increased in mammary glands of Mmtv-Ccl2
mice compared to control mice, while matrix metallo-
proteinase 2 (Mmp2), Mmp9, Timp1 and Timp2 mRNA
were not significantly altered (Fig. 5j). Combined, these
results suggest that CCL2 overexpression causes increased
abundance of stroma surrounding epithelium through
perturbation of remodelling of the extracellular matrix.
CCL2 overexpression increases susceptibility to DMBA-
induced mammary gland cancer
To investigate the effect of CCL2 overexpression on
mammary gland cancer susceptibility, control and
Mmtv-Ccl2 mice were challenged with the chemical
carcinogen DMBA. Tumour free survival was analysed
on a Kaplan–Meier plot (Fig. 6). The incidence of mam-
mary tumours was higher in Mmtv-Ccl2 mice, with 14
of 18 mice (78%) developing a mammary gland tumour
compared to 8 of 18 (44%) control mice developing a
mammary gland tumour (p = 0.04). There was also a
significant decrease in mammary tumour-free survival in
Mmtv-Ccl2 mice compared to control mice (p = 0.025);
Fig. 3 The effect of CCL2 overexpression on mammary gland morphogenesis during ovarian cycle. Mammary glands from control and Mmtv-Ccl2
mice were whole-mounted and stained with carmine alum at estrus (a, e), metestrus (b, f), diestrus (c, g) and proestrus (d, h), respectively. The number
of branch points per millimetre was calculated (k). Sections of paraffin-embedded mammary glands from control and Mmtv-Ccl2 mice at the four
stages of the cycle were H&E-stained (i, j, respectively, only proestrus stage shown) and alveolar epithelium quantified (l); n = 6–9 per group. Data are
presented as mean + SEM with statistical analysis conducted using the unpaired t test, *p < 0.05
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mean latency (mean ± SD) was 12.7 ± 1.0 weeks in
Mmtv-Ccl2 mice, and 16.7 ± 1.4 weeks in control mice.
Analysis of a subset of the tumours revealed the
majority represented adenosquamous carcinomas, with
early mammary intraepithelial neoplasia and other
carcinoma types present (Table 1). The mitotic index
and inflammation score varied widely between tumours,
and there was no significant difference in these parame-
ters between control and Mmtv-Ccl2 mice.
Epithelial cell CCL2 is increased in breast tissue of high
mammographic density in women
The increase in stroma, collagen and mammary cancer
risk in Mmtv-Ccl2 mice resembled key clinical and
histological features of HMD in women. To investigate
whether epithelial cell-derived CCL2 might be associated
with HMD, CCL2 was quantified in paired breast tissue
samples biopsied from regions of high and low density
from women undergoing prophylactic mastectomy.
Fig. 4 The effect of CCL2 overexpression on mammary epithelial cell proliferation and cell death. Paraffin-embedded sections of mammary gland tissue from
control and Mmtv-Ccl2 mice at proestrus were stained with anti-bromodeoxyuridine (BrdU) antibody to detect proliferating ductal (a and b) and alveolar
(c and d) epithelial cells. The number of BrdU-positive cells (brown-stained cells) within ductal and alveolar epithelium was calculated and expressed as BrdU-
positive cells/mm2 (i). Paraffin-embedded sections of mammary gland tissue from control and Mmtv-Ccl2 mice at proestrus were stained with TUNEL to
detect dying ductal (e and f) and alveolar (g and h) epithelial cells. The percent of TUNEL-positive cells (green-stained cells) within ductal and alveolar
epithelium was calculated (j); n= 6 per group. Data are presented as mean+ SEM with statistical analysis conducted using the unpaired t test, *p<0.05
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CCL2 staining was observed in the epithelium of human
breast tissue of low and high mammographic density,
while no staining was present in isotype-matched anti-
body control sections (Fig. 7). A few cells within the
stromal compartment also stained positive for CCL2;
however, the abundance of these scarce cells did not
appear to be affected by density. Abundance of CCL2 in
epithelial cells, as measured by intensity of CCL2 staining,
was increased in tissue with HMD compared to the paired
LMD tissue from the sample patient (p = 0.03).
Discussion
This study investigated the significance of CCL2 in
regulating macrophage recruitment, healthy mammary
gland development, and the risk of cancer. Overexpres-
sion of CCL2 by the mammary gland epithelium was
achieved through generation of a transgenic mouse
model wherein Ccl2 mRNA expression was under the
control of the mammary epithelial cell-specific promoter
MMTV. Consistent with the known role of CCL2 as
a macrophage chemoattractant [36, 37], constitutive
expression of epithelial cell-specific CCL2 resulted in
increased abundance of stromal macrophages in the
mammary gland. Therefore, this mouse model enabled
the examination of the effect of CCL2 on macrophage
infiltration, collagen remodelling, cyclic mammary gland
regression and DMBA-induced cancer risk.
CCL2 overexpression perturbs mammary gland regression
and collagen remodelling
In cycling non-pregnant mice, the mammary epithelium
undergoes ductal development and regression over the
course of each ovarian cycle under the influence of ovar-
ian hormones [31]. For the mammary gland to undergo
Fig. 5 The effect of CCL2 overexpression on abundance of stroma and collagen. Sections of mammary gland tissue from control (a, d, f) and
Mmtv-Ccl2 (b, e, h) mice at proestrus were stained with H&E (a, b), Masson’s trichrome (c, d) and collagen I antibody (g, h) and quantified (c, f, i);
n = 6 per group. Data are presented as mean + SEM with statistical analysis conducted using the unpaired t test, *p < 0.05 compared to control.
Mammary glands from both groups of mice (n = 8) were dissected and frozen in liquid nitrogen. Messenger RNAs of collagen remodelling
enzymes including Lox, Mmp2, Mmp9, Timp1, Timp2 and Timp3 were extracted and measured by RT-PCR. The amount of mRNA was normalised to
Actb expression, and is given in arbitrary units, where the average of the control is 1 (j). Data are presented as mean + SEM with statistical analysis
conducted using the unpaired t test; *p < 0.05 compared to control. LOX lysyl oxidase, MMP matrix metalloproteinase, TIMP tissue inhibitor of
matrix metalloproteinases
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these dynamic developmental processes, tight regulation
of signals within the cytokine microenvironment that
affect the balance between proliferation, differentiation,
and apoptosis, and tissue breakdown and repair is re-
quired [8, 38]. Increased ductal branch points and abun-
dance of alveolar buds observed in mice overexpressing
CCL2 at the proestrus phase of the cycle suggests that
despite normal estrous cyclicity, mammary gland regres-
sion was perturbed. However, at estrus, the mammary
epithelium exhibited a normal basic ductal structure,
implying that regression is delayed rather than com-
pletely inhibited.
Little is known of the role of CCL2 in mammary gland
development and function; however, some studies
suggest that it may be involved in mediating inflamma-
tion associated with the early response to tissue injury
and post-weaning involution. Elevated expression of
CCL2 is observed during the first stage of mammary
gland involution, where it is believed to be involved in
early recruitment of macrophages, and decreases during
the later stage of involution when tissue remodelling
peaks [39]. Lipopolysaccharide administered to the
lactating mammary gland increases abundance of CCL2,
which precedes macrophage recruitment and partial
mammary gland involution [40]. These instances of
acute elevation in CCL2 may form part of the immune
signalling fingerprint that promotes an inflammatory
response; however, later suppression of CCL2 may be
required for appropriate tissue remodelling.
Fig. 6 The effect of CCL2 overexpression on mammary gland cancer
susceptibility in mice. Kaplan–Meier survival plot showing the percentage
of tumour-free mice following 7,12-Dimethylbenz(a)anthracene (DMBA)
treatment in weeks for control and Mmtv-Ccl2 mice; n = 18 per group. In
Mmtv-Ccl2 mice, the incidence of mammary tumours was increased
(p= 0.04 chi squared) and mammary tumour-free survival was reduced
(p= 0.025 log rank) compared to control mice
Table 1 Characteristics of DMBA-induced tumours from control and Mmtv-Ccl2 mice
Genotype Latency (weeks) Histopathology Mitotic index Inflammation
Control 13 Spindeloid carcinoma 0 2
10 Adenosqaumous carcinoma 3 5
14 Adenosqaumous carcinoma 2 2
16 Early MIN 0 0
10 Adenosquamous carcinoma N/A 4
12 Adenosquamous carcinoma 1 4
11 Carcinosarcoma 0 2
10 Early MIN 0 1
Mmtv-Ccl2 10 Acinar 0 0
11 Adenosquamous carcinoma N/A 2
10 Adenosquamous carcinoma 2 5
19 Early MIN 0 0
10 Adenosqaumous carcinoma 0 2
13 Glandular carcinoma 0 2
13 Cribiform carcinoma 1 4
8 Adenosquamous carcinoma 1 5
19 Early MIN 0 0
Latency in weeks after final 7,12-Dimethylbenz(a)anthracene (DMBA) administration. Mitotic index was determined by counting the number of mitotic cells in a ×
10 field of view. Inflammation was scored as 0 (none), 1 (mild, focal), 2 (mild, multifocal), 3 (moderate, focal), 4 (moderate, multifocal) or 5 (marked, diffuse or
multifocal). MIN mammary intraepithelial neoplasia, N/A not assessed
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Mammary gland regression during the ovarian cycle
involves a series of processes, including apoptosis of the
mammary epithelial cells, clearance of dying epithelial
cells by phagocytosis and remodelling of mammary
extracellular matrix [7, 41]. Epithelial cell proliferation
and apoptosis was unaffected by constitutive expression
of the Ccl2 transgene by mammary epithelium, which
suggests that CCL2 might not affect epithelial cell turn-
over in the adult cycling mammary gland. However, the
stromal area around ductal mammary epithelium was
significantly larger in the presence of epithelial cell-
derived CCL2, and therefore CCL2 might be involved in
regulation of the process of stroma breakdown and
repair necessary for cyclic remodelling.
Mammary gland stroma is composed of extracellular
matrix proteins, and a wide variety of cells, including
fibroblasts and leukocytes such as macrophages and
eosinophils. Collagen is a prominent component of
extracellular matrix in the mammary gland stroma that
contributes significantly in supporting tissue integrity
and elasticity; furthermore; the deposition and remodel-
ling of collagen has been found to be highly associated
with normal mammary gland development and tumouri-
genesis [42–44]. Increased Timp3 mRNA expression was
observed in CCL2 overexpressing mice, indicating CCL2
may enhance the inhibitory effect of TIMPs on MMP-
mediated collagen degradation, resulting in elevated
collagen deposition. Moreover, high expression of
epithelial cell-derived CCL2 also causes increased
expression of lysyl oxidase mRNA (Lox), a collagen
crosslinking enzyme involved in crosslinking elastin and
collagen in extracellular matrix and hence, enhancing
tissue integrity [44]. This could also contribute to the
increased collagen deposition around mammary epithe-
lium in the presence of abundant CCL2, as increased
LOX expression could lead to increase mammary gland
stromal stiffness and collagen crosslinking, which could
further inhibit MMP-mediated collagen degradation.
Although mRNA for collagens and other collagen bio-
synthesis proteins were not assessed, their coordinated
upregulation is feasible.
CCL2-driven inflammation is known to promote fibro-
sis and collagen deposition in a number of disease states,
including human pulmonary fibrosis [45], bleomycin-
induced pulmonary fibrosis in rats and mice [46, 47],
and interstitial renal fibrosis in mice [48]. Macrophages
are an essential mediator of inflammation-associated
fibrosis, and have been shown to promote collagen
synthesis in vitro [49–51]. In the mammary gland,
macrophages promote collagen fibrillogenesis as a crit-
ical part of healthy pubertal development [2]. Therefore,
increased abundance of mammary gland macrophages,
stroma and collagen in CCL2 overexpressing mice is
consistent with the known role of CCL2 in driving
inflammation and collagen deposition.
These findings suggest that CCL2-driven inflammation
increases collagen deposition and inhibits collagen
remodelling around the mammary epithelium. Through
Fig. 7 CCL2 in paired samples of high and low mammographic density (MD). CCL2 immunostaining of human breast tissue of low MD (a) and
high MD (b) and isotype-matched negative control (c). Intensity of staining within the epithelium was quantified and data are presented as percent
change in abundance of CCL2 in high density tissue compared to low density tissue for each paired sample; horizontal bar indicates the mean (d)
analysis by paired sample t test (n = 13). HMD high mammographic density
Sun et al. Breast Cancer Research  (2017) 19:4 Page 12 of 15
promotion of macrophage recruitment and the activities
of TIMP3 and LOX, high CCL2 expression would be
expected to cause imbalance in the turnover of collagen,
which in turn could impair mammary gland regression
during the proestrus phase of the ovarian cycle.
CCL2-driven breast cancer risk
It is well-established that chronic inflammation increases
cancer risk through oncogenic mutations, genome in-
stability, early tumour promotion, and enhanced angio-
genesis [13, 14]. Chronic inflammation leads to collagen
deposition and fibrosis associated with increased LOX
expression [52] and increased stromal collagen depos-
ition has also long been recognised as a major contribut-
ing factor to the increased mammographic density that
increases risk of breast cancer [23, 25, 53, 54]. This
study suggests that expression of epithelial cell-specific
CCL2 by mammary epithelium increases mammary
cancer susceptibility in mice through inducing a low
level of chronic inflammation in the mammary gland,
characterised by increased macrophage infiltration and
fibrosis associated with perturbed collagen deposition
and remodelling. However, further studies to dissect the
contribution of macrophages to this phenotype are re-
quired to establish their role in the increased mammary
cancer risk observed in Mmtv-Ccl2 transgenic mice.
Population studies support the notion that increased
CCL2 expression increases breast cancer risk and cancer
progression. The risk of developing metastasis is signifi-
cantly increased in patients with breast cancer who carry
the CCL2-2518 A/G promoter polymorphism, compared
to A/A homozygotes [55]. The A/G genotype causes
increased CCL2 production in monocytes after stimula-
tion compared to the A/A genotype [56] and may simi-
larly affect CCL2 expression by mammary epithelium.
However, it is unknown whether the protein concentra-
tion of CCL2 in the transgenic mice is similar or above
the physiological concentration of CCL2 that might be
present in the human breast. In addition, altered
responsiveness to CCL2 through polymorphism in the
receptor CCR2 also affects breast cancer susceptibility.
The CCR2-64I polymorphism, which slightly impairs
capacity to transduce CCL2 signals, is underrepresented
in patients with breast cancer [17, 57], and this might
provide protection from tumour formation through
reduced recruitment of tumour-promoting macrophages.
High mammographic density is associated with
fourfold to six-fold increased breast cancer risk in the
highest versus lowest quartiles, and the association
remains after correction for BMI and age [26]. Although
the biological mechanisms that regulate mammographic
density are poorly understood, HMD is associated with
increased stroma, collagen deposition and TIMP3
protein compared to tissue of LMD [58–60]. These
biological characteristics are strikingly similar to the
mammary glands of Mmtv-Ccl2 transgenic mice, in
which overexpression of CCL2 caused increased abun-
dance of stroma, collagen thickness, mRNA encoding
TIMP3 and elevated risk of DMBA-induced mammary
cancer. An inflammatory basis for HMD is suggested by
studies in paired samples of high and low mammo-
graphic density tissue. Tissue with HMD exhibits
elevated inflammatory COX2, increased number of
vimentin-positive immune cells within the epithelium,
and reduced abundance of CD206-positive “alternatively
activated” macrophages compared to paired breast tissue
samples of LMD [25, 61, 62], and the increase in CCL2
reported here. Based on these observations, we propose
that CCL2-driven inflammation might play a role in in-
creasing mammographic density and breast cancer risk.
The potential role of inflammation in driving high
mammographic density suggests that use of non-steroidal
anti-inflammatory drugs (NSAID), which are already known
to reduce breast cancer risk [63, 64], could be effective in
reducing mammographic density. In a mouse model of
HMD, Celecoxib, a selective NSAID that specifically inhibits
COX2, was shown to reduce collagen deposition in the
mammary gland, and reduce tumour development and
metastasis [65]. Although there appears to be no association
between NSAID use and mammographic density [66], a
study of nearly 30,000 postmenopasual women found that
NSAID use reduced the risk of increasing mammographic
density over a period of 9–28 months [67]. Further studies
investigating the potential for NSAID to reduce breast
cancer risk associated with HMD are required.
Conclusion
Constitutive expression of CCL2 by the mouse mammary
epithelium induces a state of low level chronic inflammation
that perturbs collagen remodelling and elevates cancer risk.
We propose that CCL2-driven inflammation contributes to
the increased risk of breast cancer observed in women with
HMD. Future studies will examine how CCL2 is regulated
in the mammary gland, and the biological function of CCL2
in increasing mammographic density in women. Under-
standing the underlying cellular mechanisms of how inflam-
mation affects breast function will shed light on cancer
susceptibility and may uncover new opportunities to thera-
peutically reduce breast cancer risk.
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